1. Home
  2. |Insights
  3. |New Jersey Adopts the Uniform Trade Secrets Act

New Jersey Adopts the Uniform Trade Secrets Act

Client Alert | 1 min read | 01.31.12

On January 9, 2012, Governor Chris Christie signed into law the New Jersey Trade Secrets Act ("NJTSA"), which is modeled after the Uniform Trade Secrets Act ("UTSA").  New Jersey joins 45 other states and the District of Columbia in enacting a trade secret statute modeled on the UTSA.

The NJTSA generally follows the UTSA, but with a few key differences.

  • The NJTSA defines a "trade secret" more broadly than the UTSA, and extends protection to various other forms in which trade secrets can exist, including a "design, diagram, drawing, invention, plan, procedure, [or] prototype."
  • The NJTSA augments, rather than displaces, New Jersey common law remedies for misappropriation of a trade secret.
  • The NJTSA is silent as to whether courts must seek uniformity with other states applying the UTSA. 
  • The NJTSA provides greater clarity about the conduct that may give rise to a trade secrets claim, by expressly distinguishing between "proper" and "improper" means of obtaining trade secrets. Under the NJTSA, acquiring a trade secret by independent invention, reverse engineering, a license, published literature, or public observation is a complete defense.
  • The NJTSA provides a presumption in favor of granting protective orders to preserve the secrecy of an alleged trade secret during litigation.

Only four states remain without a statute modeled after the UTSA – Massachusetts, North Carolina, New York, and Texas. 

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...